These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

53 related articles for article (PubMed ID: 2515336)

  • 1. [Studies on the prevention of postoperative thrombosis with a small dose of recombinant human tissue-type plasminogen activator].
    Horimi H; Kotoda K; Yamaguchi T; Kato M; Sakata Y; Hasegawa T
    Kyobu Geka; 1989 Aug; 42(9):751-5. PubMed ID: 2515336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935).
    Agnelli G; Pascucci C; Nenci GG; Mele A; Bürgi R; Heim J
    Thromb Haemost; 1993 Aug; 70(2):294-300. PubMed ID: 8236138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Accelerated intravenous dosing of recombinant tissue-type plasminogen activator causes rapid but unstable reperfusion in a canine model of acute myocardial infarction.
    Gurbel PA; Anderson RD; MacCord CS; Scott H; Serebruany V; Herzog WR
    Coron Artery Dis; 1994 Nov; 5(11):929-36. PubMed ID: 7719525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of varying days of tissue plasminogen activator therapy on the prevention of postsurgical adhesions in a rabbit model.
    Dunn RC; Mohler M
    J Surg Res; 1993 Mar; 54(3):242-5. PubMed ID: 8474240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant full-length tissue factor pathway inhibitor (TFPI) prevents thrombus formation and rethrombosis after lysis in a rabbit model of jugular vein thrombosis.
    Kaiser B; Fareed J
    Thromb Haemost; 1996 Oct; 76(4):615-20. PubMed ID: 8903005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Does the result of thrombolysis with recombinant tissue-type plasminogen activator (rt-PA) in rabbits depend on the erythrocyte- and fibrin-content of a thrombus?].
    Kirchhof K; Sikinger M; Welzel T; Zoubaa S; Sartor K
    Rofo; 2004 Jan; 176(1):98-105. PubMed ID: 14712413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thrombolytic treatment with tissue-type plasminogen activator (t-PA) containing liposomes in rabbits: a comparison with free t-PA.
    Heeremans JL; Prevost R; Bekkers ME; Los P; Emeis JJ; Kluft C; Crommelin DJ
    Thromb Haemost; 1995 Mar; 73(3):488-94. PubMed ID: 7667833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative thrombolytic properties of tissue-type plasminogen activator and of a plasminogen activator inhibitor-1-resistant glycosylation variant, in a combined arterial and venous thrombosis model in the dog.
    Collen D; Stassen JM; Yasuda T; Refino C; Paoni N; Keyt B; Roskams T; Guerrero JL; Lijnen HR; Gold HK
    Thromb Haemost; 1994 Jul; 72(1):98-104. PubMed ID: 7974384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Plasminogen activator of tissue type. Physiology, pathophysiology and clinical value].
    Korninger C
    Wien Klin Wochenschr; 1985 Nov; 97(22):832-40. PubMed ID: 2934899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thrombolysis with recombinant human tissue-type plasminogen activator in patients with peripheral artery and bypass graft occlusions.
    Graor RA; Risius B; Lucas FV; Young JR; Ruschhaupt WF; Beven EG; Grossbard EB
    Circulation; 1986 Sep; 74(3 Pt 2):I15-20. PubMed ID: 3091288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic effect on thrombolysis of sequential infusion of tissue-type plasminogen activator (t-PA) single-chain urokinase-type plasminogen activator (scu-PA) and urokinase in the rabbit jugular vein thrombosis model.
    Collen D; Stassen JM; De Cock F
    Thromb Haemost; 1987 Oct; 58(3):943-6. PubMed ID: 3124288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The tissue-type plasminogen activator story.
    Collen D; Lijnen HR
    Arterioscler Thromb Vasc Biol; 2009 Aug; 29(8):1151-5. PubMed ID: 19605778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential role of components of the fibrinolytic system in the formation and removal of thrombus induced by endothelial injury.
    Matsuno H; Kozawa O; Niwa M; Ueshima S; Matsuo O; Collen D; Uematsu T
    Thromb Haemost; 1999 Apr; 81(4):601-4. PubMed ID: 10235447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of microvascular thrombosis with low-dose tissue plasminogen activator.
    Arnljots B; Wieslander JB; Dougan P; Salemark L
    Plast Reconstr Surg; 1992 Aug; 90(2):281-8. PubMed ID: 1631220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Local thrombolysis in peripheral arterial occlusion].
    Hess H
    Herz; 1989 Feb; 14(1):12-21. PubMed ID: 2522076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beneficial effect of aspirin in maintaining the patency of small-caliber prosthetic grafts after thrombolysis with urokinase or tissue-type plasminogen activator.
    Curl GR; Jakubowski JA; Deykin D; Bush HL
    Circulation; 1986 Sep; 74(3 Pt 2):I21-4. PubMed ID: 3091289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autologous fibrin-coated small-caliber vascular prostheses improve antithrombogenicity by reducing immunologic response.
    Hasegawa T; Okada K; Takano Y; Hiraishi Y; Okita Y
    J Thorac Cardiovasc Surg; 2007 May; 133(5):1268-76, 1276.e1. PubMed ID: 17467440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of intraocular fibrinous membrane by anterior chamber injection of tissue plasminogen activator after IOL implantation].
    Xie L; Li S; Dong X; Cao J; Shi W; Guo P
    Zhonghua Yan Ke Za Zhi; 1998 Jul; 34(4):291-3. PubMed ID: 11877211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Comparative randomized study of the effectiveness of intravenous recombinant tissue-type plasminogen activator and intravenous streptokinase in patients with acute myocardial infarct. Report of the European Cooperative Study Group for Recombinant Tissue-Type Plasminogen Activator].
    Verstraete M; Bory M; Collen D; Erbel R; Lennane RJ; Mathey D; Michels HR; Schartl M; Uebis R; Bernard R
    Klin Wochenschr; 1988; 66 Suppl 12():77-85. PubMed ID: 3126348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urokinase versus recombinant tissue plasminogen activator in thrombosed central venous catheters: a double-blinded, randomized trial.
    Haire WD; Atkinson JB; Stephens LC; Kotulak GD
    Thromb Haemost; 1994 Oct; 72(4):543-7. PubMed ID: 7878629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.